CERVARIX (HUMAN PAPILLOMAVIRUS TYPE 16, L1 CAPSID PROTEIN (RESIDUES 2-471) VACCINE 0.02 MG / HUMAN PAPILLOMAVIRUS TYPE 18, L1 CAPSID PROTEIN (RESIDUES 2-472) VACCINE 0.02 MG) PER 0.5 ML INJECTABLE SUSPENSION

Side Effects & Adverse Event Reports


0

Adverse Events

0

Side Effects

2025

Data Starting In

This report has a limited number of adverse event reports which may not fully reflect the safety profile of this product. It's important to understand that:

  • Only manufacturers are required to report adverse events — for everyone else, reporting is voluntary.
  • It's estimated that only about 10% of adverse events are ever reported.
  • Some people may not realize their experience qualifies as an adverse event.
  • Others may assume someone else has already reported the issue.
  • A lack of awareness about how and where to report can also reduce submissions.
Your report can help close this gap. Whether your experience was mild or serious, sharing it contributes to a fuller understanding of product safety and can help others make better health decisions.

SymPedia Mobile App

Get our Mobile App for easy access to the latest reports on CERVARIX (HUMAN PAPILLOMAVIRUS TYPE 16, L1 CAPSID PROTEIN (RESIDUES 2-471) VACCINE 0.02 MG / HUMAN PAPILLOMAVIRUS TYPE 18, L1 CAPSID PROTEIN (RESIDUES 2-472) VACCINE 0.02 MG) PER 0.5 ML INJECTABLE SUSPENSION.

Understanding the potential Side Effects and Adverse Events of CERVARIX (HUMAN PAPILLOMAVIRUS TYPE 16, L1 CAPSID PROTEIN (RESIDUES 2-471) VACCINE 0.02 MG / HUMAN PAPILLOMAVIRUS TYPE 18, L1 CAPSID PROTEIN (RESIDUES 2-472) VACCINE 0.02 MG) PER 0.5 ML INJECTABLE SUSPENSION is essential for making informed health decisions. Our application provides in-depth reports based on real-world data, helping you explore how CERVARIX (HUMAN PAPILLOMAVIRUS TYPE 16, L1 CAPSID PROTEIN (RESIDUES 2-471) VACCINE 0.02 MG / HUMAN PAPILLOMAVIRUS TYPE 18, L1 CAPSID PROTEIN (RESIDUES 2-472) VACCINE 0.02 MG) PER 0.5 ML INJECTABLE SUSPENSION may affect your health.

View reports containing much more information including:

  • Age group - See how different age ranges experience side effects and adverse reactions.
  • Year - Track trends over time to understand changes in reported issues.
  • Biological sex - Compare how reports vary between men and women.
  • Weight - Examine the impact of body weight on side effects and adverse events.
Download Now

Frequently Asked Questions

Some questions about CERVARIX (HUMAN PAPILLOMAVIRUS TYPE 16, L1 CAPSID PROTEIN (RESIDUES 2-471) VACCINE 0.02 MG / HUMAN PAPILLOMAVIRUS TYPE 18, L1 CAPSID PROTEIN (RESIDUES 2-472) VACCINE 0.02 MG) PER 0.5 ML INJECTABLE SUSPENSION are asked frequently. We've answered the most frequent of those questions below

  • How many adverse events have been reported for CERVARIX (HUMAN PAPILLOMAVIRUS TYPE 16, L1 CAPSID PROTEIN (RESIDUES 2-471) VACCINE 0.02 MG / HUMAN PAPILLOMAVIRUS TYPE 18, L1 CAPSID PROTEIN (RESIDUES 2-472) VACCINE 0.02 MG) PER 0.5 ML INJECTABLE SUSPENSION?

    SymPedia shows CERVARIX (HUMAN PAPILLOMAVIRUS TYPE 16, L1 CAPSID PROTEIN (RESIDUES 2-471) VACCINE 0.02 MG / HUMAN PAPILLOMAVIRUS TYPE 18, L1 CAPSID PROTEIN (RESIDUES 2-472) VACCINE 0.02 MG) PER 0.5 ML INJECTABLE SUSPENSION adverse event reports for 0.

  • How many side effects have been reported for CERVARIX (HUMAN PAPILLOMAVIRUS TYPE 16, L1 CAPSID PROTEIN (RESIDUES 2-471) VACCINE 0.02 MG / HUMAN PAPILLOMAVIRUS TYPE 18, L1 CAPSID PROTEIN (RESIDUES 2-472) VACCINE 0.02 MG) PER 0.5 ML INJECTABLE SUSPENSION?

    SymPedia shows CERVARIX (HUMAN PAPILLOMAVIRUS TYPE 16, L1 CAPSID PROTEIN (RESIDUES 2-471) VACCINE 0.02 MG / HUMAN PAPILLOMAVIRUS TYPE 18, L1 CAPSID PROTEIN (RESIDUES 2-472) VACCINE 0.02 MG) PER 0.5 ML INJECTABLE SUSPENSION side effect reports for 0.

  • What year does the CERVARIX (HUMAN PAPILLOMAVIRUS TYPE 16, L1 CAPSID PROTEIN (RESIDUES 2-471) VACCINE 0.02 MG / HUMAN PAPILLOMAVIRUS TYPE 18, L1 CAPSID PROTEIN (RESIDUES 2-472) VACCINE 0.02 MG) PER 0.5 ML INJECTABLE SUSPENSION reporting data start?

    SymPedia reporting data on this page starts in 2025.

  • What years are included in the yearly chart for CERVARIX (HUMAN PAPILLOMAVIRUS TYPE 16, L1 CAPSID PROTEIN (RESIDUES 2-471) VACCINE 0.02 MG / HUMAN PAPILLOMAVIRUS TYPE 18, L1 CAPSID PROTEIN (RESIDUES 2-472) VACCINE 0.02 MG) PER 0.5 ML INJECTABLE SUSPENSION?

    SymPedia yearly chart data is not available for this page.

  • Is adverse event reporting mandatory?

    SymPedia notes that only manufacturers are required to report adverse events. For other reporters, submission is generally voluntary, which can lead to underreporting.